PODD
Insulet Corporation
$154.87
-2.02
(-1.29%)
Mkt Cap
10.73B
Volume
938,925
52W Range
145.59-354.88
Sector
Healthcare
Beta
1.20
EPS (TTM)
4.31
P/E Ratio
35.93
Revenue (TTM)
2.90B
Rev Growth (5Y)
+24.5%
EPS Growth (5Y)
+99.9%
AlphaVal · Fair Value
$181.02
Fair Value · Mild
14.4% below fair value
AlphaQuality · Grade
B-
Platform & Compounding FCF
64.3 / 100 composite
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B | 904.40M | 738.20M | 563.82M | 463.77M | 366.99M | 263.89M | 288.72M |
| Net Income | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M | 6.80M | 11.60M | 3.29M | (26.83M) | (28.88M) | (73.52M) | (51.50M) |
| EPS | 3.51 | 5.97 | 2.96 | 0.07 | 0.25 | 0.11 | 0.19 | 0.06 | -0.46 | -0.51 | -1.29 | -0.93 |
| Free Cash Flow | 377.70M | 305.40M | 70.10M | (38.30M) | (190.80M) | (82.50M) | (72.50M) | (126.45M) | (36.02M) | (6.20M) | N/A | N/A |
| FCF / Share | 5.37 | 4.36 | 1.01 | -0.55 | -2.82 | -1.27 | -1.20 | -2.15 | -0.62 | -0.11 | N/A | N/A |
| Operating CF | 569.30M | 430.30M | 145.70M | 119.00M | (68.10M) | 84.00M | 98.40M | 35.90M | 41.30M | 15.91M | N/A | N/A |
| Total Assets | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B | 1.87B | 1.14B | 928.74M | 816.74M | 456.65M | N/A | N/A |
| Total Debt | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B | 1.08B | 905.90M | 591.98M | 566.17M | 333.04M | N/A | N/A |
| Cash & Equiv | 716.10M | 953.40M | 650.70M | 623.90M | 791.60M | 907.20M | 203.70M | 113.91M | 272.58M | 137.17M | N/A | N/A |
| Book Value | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M | 603.60M | 75.90M | 212.10M | 158.52M | 63.15M | N/A | N/A |
| Return on Equity | 0.16 | 0.35 | 0.28 | 0.01 | 0.03 | 0.01 | 0.15 | 0.02 | -0.17 | -0.46 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761.70M | 783.80M | 706.30M | 649.10M | 569.00M | 597.50M | 543.90M | 488.50M | 441.70M | 509.80M | 432.70M | 396.50M |
| Net Income | 91.10M | 101.60M | 87.60M | 22.50M | 35.40M | 100.70M | 77.50M | 188.60M | 51.50M | 103.30M | 51.90M | 27.30M |
| EPS | 1.30 | 1.45 | 1.24 | 0.32 | 0.50 | 1.44 | 1.11 | 2.69 | 0.74 | 1.48 | 0.74 | 0.39 |
| Free Cash Flow | 86.00M | 48.20M | 104.70M | 173.30M | 51.50M | 91.70M | 71.80M | 64.30M | 63.60M | 47.20M | 33.60M | 25.90M |
| FCF / Share | 1.23 | 0.69 | 1.48 | 2.46 | 0.73 | 1.31 | 1.02 | 0.92 | 0.91 | 0.68 | 0.48 | 0.37 |
| Operating CF | 113.80M | 183.30M | 125.70M | 196.50M | 63.80M | 147.70M | 98.50M | 86.80M | 87.60M | 45.20M | 56.00M | 44.00M |
| Total Assets | 2.99B | 3.19B | 3.03B | 3.47B | 3.52B | 3.09B | 3.03B | 2.88B | 2.62B | 2.59B | 2.47B | 2.39B |
| Total Debt | 948.10M | 1.05B | 1.03B | 1.42B | 1.70B | 1.42B | 1.40B | 1.40B | 1.40B | 1.45B | 1.42B | 1.40B |
| Cash & Equiv | 480.40M | 716.10M | 757.40M | 992.90M | 1.28B | 953.40M | 902.60M | 715.50M | 696.90M | 650.70M | 580.70M | 556.80M |
| Book Value | 1.30B | 1.52B | 1.38B | 1.46B | 1.33B | 1.21B | 1.12B | 998.40M | 790.70M | 732.70M | 607.50M | 553.90M |
| Return on Equity | 0.07 | 0.07 | 0.06 | 0.02 | 0.03 | 0.08 | 0.07 | 0.19 | 0.07 | 0.14 | 0.09 | 0.05 |
PODD News
Insulet Corp (PODD) Shares Surge 3.5% -- What GF Score of 82 Tells Investors
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insulet: An Opportune Time To Get Involved
Here's Why Insulet (PODD) is a Strong Growth Stock
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe’s, Matador Resources, Toast and More
Why Insulet (PODD) is a Top Value Stock for the Long-Term
Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript
Insulet (PODD) Loses 17.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Insulet lifts annual revenue forecast after quarterly beat on strong insulin pump demand